Use of an amphotericin B lipid complex for treatment of blastomycosis in dogs

Donald R. Krawiec From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Donald R. Krawiec in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Brendan C. McKiernan From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Brendan C. McKiernan in
Current site
Google Scholar
PubMed
Close
 DVM
,
A. Robert Twardock From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by A. Robert Twardock in
Current site
Google Scholar
PubMed
Close
 DVM, PhD
,
Christine E. Swenson From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Christine E. Swenson in
Current site
Google Scholar
PubMed
Close
 PhD
,
Randall J. Itkin From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Randall J. Itkin in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Lynelle R. Johnson From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Lynelle R. Johnson in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Lisa K. Kurowsky From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Lisa K. Kurowsky in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Carol A. Marks From the Departments of Veterinary Clinical Medicine (Krawiec, McKiernan, Kurowsky, Marks), and Veterinary Biosciences (Twardock), College of Veterinary Medicine, University of Illinois, Urbana, IL 61801; The Liposome Company Inc, Princeton, NJ 08540-6619 (Swenson); 61 E 96th St, Indianapolis, IN 64240 (Itkin); and the Department of Biomedical Sciences, E102 Veterinary Medicine, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Carol A. Marks in
Current site
Google Scholar
PubMed
Close
 DVM, MS

Click on author name to view affiliation information

Objective

To evaluate efficacy and nephrotoxicity of amphotericin B lipid complex used for treatment of dogs with naturally developing blastomycosis.

Design

Prospective clinical trial.

Animals

11 dogs with blastomycosis.

Procedure

All dogs were treated with an amphotericin B lipid complex. Two dogs received a cumulative dose of 8 mg/kg of body weight, 1 received a cumulative dose of 10 mg/kg, and 8 received a cumulative dose of 12 mg/kg.

Results

The 2 dogs that received a cumulative dose of 8 mg/kg and 1 of the dogs that received a cumulative dose of 12 mg/kg had a relapse of blastomycosis within 30 days after treatment. Seven of the remaining 8 dogs were clinically free of blastomycosis 6 months after treatment. One dog died of an unrelated cause 5.5 months after treatment, but did not have clinical signs of blastomycosis at the time of death. There were not any adverse clinical effects attributable to drug administration in any of the dogs in this study, and none of the dogs developed clinical signs of renal disease or failure.

Clinical Implications

Amphotericin B lipid complex was a safe and effective treatment for blastomycosis in these dogs. (J Am Vet Med Assoc 1996;209:2073–2075)

Objective

To evaluate efficacy and nephrotoxicity of amphotericin B lipid complex used for treatment of dogs with naturally developing blastomycosis.

Design

Prospective clinical trial.

Animals

11 dogs with blastomycosis.

Procedure

All dogs were treated with an amphotericin B lipid complex. Two dogs received a cumulative dose of 8 mg/kg of body weight, 1 received a cumulative dose of 10 mg/kg, and 8 received a cumulative dose of 12 mg/kg.

Results

The 2 dogs that received a cumulative dose of 8 mg/kg and 1 of the dogs that received a cumulative dose of 12 mg/kg had a relapse of blastomycosis within 30 days after treatment. Seven of the remaining 8 dogs were clinically free of blastomycosis 6 months after treatment. One dog died of an unrelated cause 5.5 months after treatment, but did not have clinical signs of blastomycosis at the time of death. There were not any adverse clinical effects attributable to drug administration in any of the dogs in this study, and none of the dogs developed clinical signs of renal disease or failure.

Clinical Implications

Amphotericin B lipid complex was a safe and effective treatment for blastomycosis in these dogs. (J Am Vet Med Assoc 1996;209:2073–2075)

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 258 258 147
PDF Downloads 25 25 2
Advertisement